Veeva Systems Inc. $VEEV Shares Sold by Curated Wealth Partners LLC

Curated Wealth Partners LLC trimmed its position in Veeva Systems Inc. (NYSE:VEEV) by 45.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,924 shares of the technology company’s stock after selling 3,291 shares during the quarter. Curated Wealth Partners LLC’s holdings in Veeva Systems were worth $1,120,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in VEEV. Lodestone Wealth Management LLC raised its holdings in shares of Veeva Systems by 68.3% during the third quarter. Lodestone Wealth Management LLC now owns 138 shares of the technology company’s stock valued at $39,000 after acquiring an additional 56 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its stake in Veeva Systems by 1.2% in the third quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,664 shares of the technology company’s stock worth $1,331,000 after acquiring an additional 57 shares during the period. Argos Wealth Advisors LLC boosted its holdings in Veeva Systems by 3.9% in the first quarter. Argos Wealth Advisors LLC now owns 1,720 shares of the technology company’s stock valued at $302,000 after acquiring an additional 65 shares in the last quarter. Toth Financial Advisory Corp boosted its holdings in Veeva Systems by 24.1% in the third quarter. Toth Financial Advisory Corp now owns 335 shares of the technology company’s stock valued at $96,000 after acquiring an additional 65 shares in the last quarter. Finally, Cim LLC boosted its holdings in Veeva Systems by 1.2% in the first quarter. Cim LLC now owns 5,778 shares of the technology company’s stock valued at $1,015,000 after acquiring an additional 66 shares in the last quarter. 88.20% of the stock is owned by hedge funds and other institutional investors.

Veeva Systems News Summary

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Expanded IQVIA agreement strengthens Veeva’s market position. IQVIA plans to make Veeva’s Clinical Trial Management System, electronic Trial Master File, Study Startup, and Site Connect products enterprise standards across its global research operations. The agreement expands an existing relationship and could increase recurring revenue, workflow integration, and customer reach. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
• Positive Sentiment: Adoption among emerging biotechs is broadening. More than 175 emerging biotechnology companies are reportedly using Veeva Basics, supporting the company’s strategy of building early relationships that may develop into larger, long-term customers as these firms advance their drug pipelines. Veeva Systems’ Basics Gains Traction With 175+ Emerging Biotech Firms
• Positive Sentiment: Analyst sentiment remains supportive. Oppenheimer maintained a $325 price target, while Zacks highlighted a favorable average brokerage recommendation. The target is only modestly above recent trading levels, and Zacks cautioned that sell-side recommendations can be overly optimistic, but the coverage is helping reinforce the bullish narrative. Oppenheimer Keeps USD 325 Target for Veeva Systems Stock
• Positive Sentiment: Technical momentum has attracted institutional interest. The stock broke above a reported buy point as investors sought exposure to Veeva’s cloud and AI-related software opportunity, adding momentum to the recent advance. Veeva Stock Breaks Out as Big Money Grabs Exposure to the AI Software Play
• Neutral Sentiment: Veeva will host a virtual investor day on November 5, which could provide updates on strategy, growth opportunities, and financial targets. Broader life-sciences IT market growth also provides a favorable backdrop, although neither item changes current earnings expectations. Veeva to Host Virtual Investor Day

Veeva Systems Trading Up 4.8%

VEEV traded up $14.18 during trading on Thursday, reaching $311.53. The stock had a trading volume of 1,323,190 shares, compared to its average volume of 2,321,903. The company has a market capitalization of $50.44 billion, a price-to-earnings ratio of 51.34, a P/E/G ratio of 1.29 and a beta of 0.93. The stock’s 50 day moving average is $266.28 and its two-hundred day moving average is $206.24. Veeva Systems Inc. has a one year low of $148.05 and a one year high of $313.52.

Veeva Systems (NYSE:VEEV) last announced its earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The firm had revenue of $927.96 million for the quarter, compared to analysts’ expectations of $905.38 million. During the same quarter in the previous year, the business posted $1.99 EPS. The company’s quarterly revenue was up 17.6% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, equities research analysts predict that Veeva Systems Inc. will post 6.70 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on VEEV. Mizuho upped their price objective on shares of Veeva Systems from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Citigroup lifted their target price on shares of Veeva Systems from $190.00 to $273.00 and gave the company a “neutral” rating in a research note on Friday, August 28th. Wall Street Zen upgraded shares of Veeva Systems from a “hold” rating to a “buy” rating in a research report on Saturday, October 10th. UBS Group boosted their price target on shares of Veeva Systems from $190.00 to $290.00 and gave the company a “neutral” rating in a research report on Thursday, August 27th. Finally, Guggenheim increased their price target on shares of Veeva Systems from $276.00 to $310.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Nineteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $285.92.

Insider Buying and Selling

In other Veeva Systems news, insider Thomas D. Schwenger sold 10,000 shares of Veeva Systems stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $281.33, for a total transaction of $2,813,300.00. Following the completion of the transaction, the insider owned 19,449 shares in the company, valued at approximately $5,471,587.17. The trade was a 33.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Priscilla Hung sold 750 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total value of $195,780.00. Following the completion of the sale, the director directly owned 3,242 shares in the company, valued at $846,291.68. This trade represents a 18.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 51,591 shares of company stock worth $13,355,945 in the last 90 days. Insiders own 10.60% of the company’s stock.

Veeva Systems Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.